Big Pharma, Drug Testing Firms Push Back on Cannabis Rescheduling
Pharmaceutical and drug testing companies warn Trump administration that moving cannabis to Schedule III will drive increased substance abuse nationwide.
Pharmaceutical companies and drug testing industry players are mounting opposition to cannabis rescheduling efforts, arguing that moving marijuana from Schedule I to Schedule III will trigger widespread substance abuse. The pushback comes as the Trump administration evaluates the DEA's cannabis classification review initiated under the previous administration.
The pharmaceutical industry's resistance reflects broader concerns about cannabis competing with prescription medications for pain management, anxiety, and sleep disorders. Companies producing opioids, benzodiazepines, and sleep aids face potential market share erosion as medical cannabis programs expand nationwide. This opposition mirrors similar lobbying efforts that emerged during state-level legalization campaigns, where pharma spending consistently supported prohibition measures.
Drug testing companies stand to lose revenue streams if federal rescheduling reduces workplace cannabis screening requirements. Current Schedule I classification enables strict employment policies across federal contractors and safety-sensitive industries. Moving to Schedule III could prompt policy changes that treat cannabis more like prescription medications, potentially limiting testing scenarios and reducing demand for screening services.
The timing of this industry pushback coincides with growing bipartisan support for cannabis reform and state-level market expansion. Over 40 states now permit some form of medical cannabis, generating billions in annual revenue while demonstrating regulated market viability. Multi-state operators like Curaleaf, Green Thumb Industries, and Trulieve continue expanding operations despite federal scheduling constraints, suggesting market momentum remains strong regardless of industry opposition.
Trump's ultimate decision on rescheduling will balance competing interests including criminal justice reform advocates, state-legal cannabis businesses, and traditional pharmaceutical lobbying power. The administration faces pressure to address the disconnect between federal prohibition and widespread state acceptance, while navigating opposition from established healthcare industry players protecting existing market positions.